Cantor Fitzgerald Reiterates Sell on bluebird bio (BLUE) Following ASH Abstracts

November 3, 2016 11:19 AM EDT
Get Alerts BLUE Hot Sheet
Price: $69.50 -3.2%

Rating Summary:
    15 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade BLUE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Elemer Piros reiterated a Sell rating and $37 price target on bluebird bio (NASDAQ: BLUE) following this morning's ASH abstracts.

Piros highlighted:

  • As telegraphed by the company at a recent investor/analyst day, at the upcoming ASH conference, we would only see results from patients that were treated with previous treatment process.
  • The abstracts released this morning confirmed this information.
  • In September, bluebird initiated trials with an improved process anticipating more robust and less variable outcomes in homozygous thalassemia and sickle cell disease patients.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $46.40 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Cantor Fitzgerald

Add Your Comment